These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23686525)

  • 41. ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.
    Capala ME; Vellenga E; Schuringa JJ
    PLoS One; 2014; 9(10):e111568. PubMed ID: 25360637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
    Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
    Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms.
    Martelli AM; Papa V; Tazzari PL; Ricci F; Evangelisti C; Chiarini F; Grimaldi C; Cappellini A; Martinelli G; Ottaviani E; Pagliaro P; Horn S; Bäsecke J; Lindner LH; Eibl H; McCubrey JA
    Leukemia; 2010 Apr; 24(4):687-98. PubMed ID: 20200557
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities.
    Costello RT; Mallet F; Gaugler B; Sainty D; Arnoulet C; Gastaut JA; Olive D
    Cancer Res; 2000 Aug; 60(16):4403-11. PubMed ID: 10969785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
    Herrmann H; Kneidinger M; Cerny-Reiterer S; Rülicke T; Willmann M; Gleixner KV; Blatt K; Hörmann G; Peter B; Samorapoompichit P; Pickl W; Bharate GY; Mayerhofer M; Sperr WR; Maeda H; Valent P
    Curr Cancer Drug Targets; 2012 Jan; 12(1):51-63. PubMed ID: 22165967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Takeuchi A; Nobumoto A; Tsuda M; Yokoyama A
    Leukemia; 2015 Dec; 29(12):2296-306. PubMed ID: 26260387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
    Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
    Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
    [TBL] [Abstract][Full Text] [Related]  

  • 48. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
    [No Abstract]   [Full Text] [Related]  

  • 49. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets.
    Su R; Lin HS; Zhang XH; Yin XL; Ning HM; Liu B; Zhai PF; Gong JN; Shen C; Song L; Chen J; Wang F; Zhao HL; Ma YN; Yu J; Zhang JW
    Oncogene; 2015 Jun; 34(25):3226-39. PubMed ID: 25174404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity.
    She M; Niu X; Chen X; Li J; Zhou M; He Y; Le Y; Guo K
    Cancer Lett; 2012 May; 318(2):173-9. PubMed ID: 22198207
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
    Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia.
    Qi J; Gao X; Zhong X; Zhang N; Wang R; Zhang H; Pan T; Liu X; Yao Y; Wu Q; Niu M; Xu K
    Biomed Pharmacother; 2019 Sep; 117():109113. PubMed ID: 31207577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+ /CD38- cells and sensitizes them to antileukemia agents.
    Ikezoe T; Yang J; Nishioka C; Kojima S; Takeuchi A; Phillip Koeffler H; Yokoyama A
    Int J Cancer; 2011 May; 128(10):2317-25. PubMed ID: 21128225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia.
    Nakamura S; Tan L; Nagata Y; Takemura T; Asahina A; Yokota D; Yagyu T; Shibata K; Fujisawa S; Ohnishi K
    Mol Carcinog; 2013 Jan; 52(1):57-69. PubMed ID: 22086844
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BH3 mimetic ABT-737 induces apoptosis in CD34
    Rao J; Li F; Zhang RY; Zhou HH; Chen GA
    Asia Pac J Clin Oncol; 2017 Apr; 13(2):e144-e152. PubMed ID: 26552712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia.
    Moshaver B; van Rhenen A; Kelder A; van der Pol M; Terwijn M; Bachas C; Westra AH; Ossenkoppele GJ; Zweegman S; Schuurhuis GJ
    Stem Cells; 2008 Dec; 26(12):3059-67. PubMed ID: 19096043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metformin as an Enhancer for the Treatment of Chemoresistant CD34+ Acute Myeloid Leukemia Cells.
    Krastinaite I; Charkavliuk S; Navakauskiene R; Borutinskaite VV
    Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osteopontin plays a unique role in resistance of CD34+/CD123+ human leukemia cell lines KG1a to parthenolide.
    Mohammadi S; Zahedpanah M; Ghaffari SH; Shaiegan M; Nikbakht M; Nikugoftar M
    Life Sci; 2017 Nov; 189():89-95. PubMed ID: 28935249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma.
    Park SI; Lin CP; Ren N; Angus SP; Dittmer DP; Foote M; Parton T; Bhatt AP; Fedoriw YD; Roth DP; Cann ML; Johnson GL; Damania B
    Target Oncol; 2019 Oct; 14(5):563-575. PubMed ID: 31429028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.